News Release

Health outcomes, cost-effectiveness of monoclonal SARS-CoV-2 antibodies as pre-exposure prophylaxis

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: This decision analytic model showed that within the context of a high SARS-CoV-2 probability, monoclonal antibodies pre-exposure prophylaxis (mAbs PrEP) provision was cost-saving when provided to individuals at increased risk of severe COVID-19 if drug prices decrease to $275 and effectiveness is 75% or higher. When newer mAbs PrEP combinations become available, guidance on implementation should be formulated ensuring a fast rollout. Nevertheless, advocacy for mAbs PrEP use and critical discussion on drug prices are necessary to ensuring cost-effectiveness for different epidemic settings. 

Authors: Stephanie Popping, M.D., Ph.D., of the University of Amsterdam, is the corresponding author. 

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.